Positive 48-week results from PEGASUS Phase III study of pegcetacoplan in paroxysmal nocturnal haemoglobinuria

In the 77 patients who completed the 16-week randomised phase and entered the open-label period, receiving pegcetacoplan from week 17-48, the mean improvement in haemoglobin from baseline was sustained, at 2.7g/dL (equal to that seen at week 16 in pegcetacoplan-treated patients).

Source:

Biospace Inc.